CARDIFF, Calif., March 8, 2012 /PRNewswire/ -- NI Research, the publisher of independent and authoritative reviews of the neurotherapeutics area, has released the 2012 edition of the Private CNS Company Review. PCNS provides a unique database of information about the private companies specializing in the development of novel therapeutics for neurological/psychiatric disorders. PCNS describes and appraises scientific platforms; clinical/preclinical activity; contact information; alliances; financing; prospects, and licensing opportunities.
"In an era where many major pharmaceutical companies are still trying to develop a coherent and effective strategy for neuroscience, much of the most creative and promising R&D for neurotherapeutics is being carried out by privately held companies. The 138 companies reviewed in PCNS cover the full gamut of innovation, from those addressing highly innovative albeit risky novel targets, to companies developing clinical-stage modifications of familiar mechanistic themes," notes Harry Tracy, PhD, President of NI Research (http://www.niresearch.com).
"Not all of them are going to be productive; there is both excellence and mediocrity to be found in this group, but any large or midsize pharmaceutical company intending to participate in the next generation of neurotherapeutics must pay close attention to the programs in development by these firms. No other publication focuses on this area with the depth and comprehensiveness of PCNS; it is a unique resource for Business Development teams at companies of any size," said Tracy, who provides consultation services to the neuropharm industry.
The Table of Contents for the 2012 edition of the Private CNS Company Review:
Private CNS Company Fates/Casualties
Private CNS Company Destinations
Private CNS Company Funding 2011
Opportunities by Stage of Development
2012 PCNS Inflection Points
Top Five PCNS Partnering Opportunities
Four PCNS Subsets: Neurotrophic Factors, Novel Pain Mechanisms, Novel Antidepressants, Novel Schizophrenia Drug Mechanisms
American Life Science Pharmaceuticals
Dart Neuroscience/Helicon Therapeutics
MSI Methylation Sciences
New World Laboratories
SCT Spinal Cord Therapeutics
On the Cusp ...
Programs by Company, Indication, Stage
VC CNS Portfolios
Private CNS Company Review 2012 is the annual, independent review of the private neuroscience company universe. The cost of PCNS 2012 is $4,000 for NeuroPerspective subscribers, $5,000 for nonsubscribers. Startup companies can contact us for pricing options.
About NI Research
NI Research is the leading publisher of independent research on the neuropharmaceutical/therapeutic industry. NI Research has published NeuroPerspective (formerly NeuroInvestment) since 1995; the Private CNS Company Review since 2003; and CNS Therapeutics and Licensing since 2007. NI Research has developed an unmatched information base regarding both publicly and privately held neurotherapeutics companies, and offers M&A/licensing consultation services.
For information, go to http://www.niresearch.com
SOURCE NI Research